Institute of Parasitology and Biomedicine Lopez-Neyra, Consejo Superior Investigaciones Cientificas, Granada 18016, Spain.
School of Medicine, Castilla La Mancha University, Ciudad Real 13071, Spain.
J Immunol. 2018 Jun 1;200(11):3697-3710. doi: 10.4049/jimmunol.1800122. Epub 2018 Apr 18.
Vasoactive intestinal peptide (VIP) is a neuropeptide that exerts various vascular and cardioprotective functions and regulates immune function and inflammatory response at multiple levels. However, its role in inflammatory cardiovascular disorders is largely unknown. Myocarditis and atherosclerosis are two inflammatory and autoimmune cardiovascular diseases that cause important adverse circulatory events. In this study, we investigate the therapeutic effects of VIP in various well-established preclinical models of experimental autoimmune myocarditis and atherosclerosis. Intraperitoneal injection of VIP during the effector phase of experimental autoimmune myocarditis in susceptible BALB/c mice significantly reduced its prevalence, ameliorated signs of heart hypertrophy and injury, attenuated myocardial inflammatory infiltration, and avoided subsequent profibrotic cardiac remodeling. This effect was accompanied by a reduction of Th17-driven cardiomyogenic responses in peripheral lymphoid organs and in the levels of myocardial autoantibodies. In contrast, acute and chronic atherosclerosis was induced in apolipoprotein E-deficient mice fed a hyperlipidemic diet and subjected to partial carotid ligation. Systemic VIP treatment reduced the number and size of atherosclerotic plaques in carotid, aorta, and sinus in hypercholesterolemic mice. VIP reduced Th1-driven inflammatory responses and increased regulatory T cells in atherosclerotic arteries and their draining lymph nodes. VIP also regulated cholesterol efflux in macrophages and reduced the formation of foam cells and their presence in atherosclerotic plaques. Finally, VIP inhibited proliferation and migration of smooth muscle cells and neointima formation in a mouse model of complete carotid ligation. These findings encourage further studies aimed to assess whether VIP can be used as a pharmaceutical agent to treat heart inflammation and atherosclerosis.
血管活性肠肽(VIP)是一种神经肽,它在多个水平上发挥多种血管和心脏保护功能,并调节免疫功能和炎症反应。然而,它在炎症性心血管疾病中的作用在很大程度上是未知的。心肌炎和动脉粥样硬化是两种炎症性和自身免疫性心血管疾病,它们导致重要的不良循环事件。在这项研究中,我们研究了 VIP 在各种成熟的实验性自身免疫性心肌炎和动脉粥样硬化的临床前模型中的治疗效果。在易感 BALB/c 小鼠的实验性自身免疫性心肌炎效应期腹腔内注射 VIP 可显著降低其发生率,改善心脏肥大和损伤的迹象,减轻心肌炎症浸润,并避免随后的促纤维化心脏重塑。这种作用伴随着外周淋巴器官和心肌自身抗体水平的 Th17 驱动的心肌生成反应减少。相比之下,在高脂饮食喂养的载脂蛋白 E 缺陷小鼠中诱导急性和慢性动脉粥样硬化,并进行部分颈动脉结扎。全身 VIP 治疗可减少高脂血症小鼠颈动脉、主动脉和窦部粥样硬化斑块的数量和大小。VIP 减少了动脉粥样硬化血管及其引流淋巴结中的 Th1 驱动的炎症反应,并增加了调节性 T 细胞。VIP 还调节了巨噬细胞中的胆固醇流出,并减少了泡沫细胞的形成及其在粥样硬化斑块中的存在。最后,VIP 抑制了完全颈动脉结扎小鼠模型中平滑肌细胞的增殖和迁移以及新内膜的形成。这些发现鼓励进一步研究,以评估 VIP 是否可作为治疗心脏炎症和动脉粥样硬化的药物。